Reuters logo
BRIEF-GNI Group gets IND clearance by FDA for liver fibrosis treatment
October 9, 2017 / 8:13 PM / 9 days ago

BRIEF-GNI Group gets IND clearance by FDA for liver fibrosis treatment

Oct 9 (Reuters) - GNI Group Ltd

* GNI Group announces clearance of investigational new drug (IND) by FDA for F351 clinical trials in the treatment of liver fibrosis

* ‍GNI Group ltd does not expect submission will impact financial results for year ending December 31, 2017​

* ‍GNI USA intends to initiate necessary procedures to start a phase I open label study in U.S. in early 2018​

* Preliminary results are expected within 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below